top of page
  • Active, not recruiting

NCT03215524: Phase 2 - Daratumumab, Low-Dose Dex and Cyclophosphamide +/- Pomalidomide (DCDP)

Updated: May 6, 2022

A Study Of Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without Pomalidomide (DCDP)

This is a randomized phase II open label study of daratumumab, weekly low-dose oral cyclophosphamide and dexamethasone with or without pomalidomide in patients with relapsed and refractory multiple myeloma. The study consists of two arms. Patients will be randomized into ARM A and ARM B in a 1:1 ratio.

Sponsor: Canadian Myeloma Research Group Identifier: NCT03215524

Official Title: A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide With or Without Pomalidomide in Patients With Relapsed and Refractory Multiple Myeloma



Biological: DCdP

Biological: DCd+P


Posts Archive
bottom of page